CNN recently posted the below article reporting on the disappointing results of the DBV Technologies late-stage clinical trail results for its patch vaccine, Viaskin Peanut.
“The trial results were recently released (Phase 3, the final phase before FDA approval). It seemed that in the study of about 300 individuals with confirmed/documented peanut allergy about 35% of patients responded, but that was not sufficient to meet the primary endpoint of response. As such, it is likely that the patch will need at the least another large trial to prove it works before it becomes an option, if it will ever be an option. There is another trial of a peanut capsule, to be taken orally with defined doses of peanut protein (a more specific, precise way to dose and perform oral immunotherapy), that is ongoing with results expected in early 2018.” – Dr. Jain
Click here to read the full article.
